What changed
$GILD — Develops and markets innovative biopharmaceutical therapies.
🎯 Q1 FY26 | Rev $7B | EPS $2.03 vs $1.91 🟢 | Margin 37.2%
💡 Consensus expects GILD to be a slow-growth, patent-cliff story with HIV revenue peaking. The Q1 beat (EPS $2.03 vs $1.91) and raised full-year product sales guidance to $30.0-30.4B (from $29.6-30.0B) signal that the core HIV franchise (Biktarvy) is holding up better than feared, and the pipeline (Trodelvy, cell therapy) is contributing incremental...
🏢 Business Quality: 7/10 | Valuation: fair
📉 Reward/Risk: Upside 15% to $140 (10x 2026 EPS of $14.00) vs downside 10% to $109 (8.5x same EPS). Ratio 1.5:1.
🔮 Catalyst: Upcoming data readouts for Trodelvy in 2L NSCLC (mid-2026) and HIV lenacapavir long-acting data (H2 2026). Metric: Trodelvy OS benefit in NSCLC. Failure signal: negative data or regulatory delay.
💰 Entry: Current $121.48 is attractive.
Also in play: $AMGN $BIIB $REGN $VRTX $GILD $CTLT